Ambrisentan (Myogen).
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BASF Pharma), for the potential treatment of post-ischemic acute renal failure and cardiovascular disease . By August 2001, ambrisentan had entered phase II trials for chronic heart failure, hypertension, kidney failure and pulmonary hypertension.